Literature DB >> 20005150

Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Brian Ruffell1, David G DeNardo, Nesrine I Affara, Lisa M Coussens.   

Abstract

The classic view that the role of immune cells in cancer is primarily one of tumor rejection has been supplanted by a more complex view of leukocytes having both pro- and anti-tumor properties. This shift is due to the now well recognized capabilities of several myeloid cell types that foster pro-tumor programming of premalignant tissue, as well as the discovery that subsets of leukocytes also suppress development and effector functions of lymphocytes important for mediating anti-tumor immunity. In this review, we focus on the underappreciated role that T lymphocytes play in promoting tumor development. This includes, in addition to the role of T regulatory cells, a role for natural killer T cells and CD4(+) T helper cells in suppressing anti-tumor immunity and promoting cancer growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005150      PMCID: PMC2834837          DOI: 10.1016/j.cytogfr.2009.11.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  131 in total

Review 1.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

Authors:  Frances Balkwill; Kellie A Charles; Alberto Mantovani
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

2.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.

Authors:  I Toura; T Kawano; Y Akutsu; T Nakayama; T Ochiai; M Taniguchi
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

3.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 4.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

5.  Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.

Authors:  F Fallarino; T F Gajewski
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

6.  De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.

Authors:  J Ignacio Herrero; María Lorenzo; Jorge Quiroga; Bruno Sangro; Fernando Pardo; Fernando Rotellar; Javier Alvarez-Cienfuegos; Jesús Prieto
Journal:  Liver Transpl       Date:  2005-01       Impact factor: 5.799

7.  CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.

Authors:  Dylan Daniel; Christopher Chiu; Enrico Giraudo; Masahiro Inoue; Lee A Mizzen; N Randall Chu; Douglas Hanahan
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.

Authors:  Nadine Y Crowe; Mark J Smyth; Dale I Godfrey
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

9.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Suppression of lymphoma and epithelial malignancies effected by interferon gamma.

Authors:  Shayna E A Street; Joseph A Trapani; Duncan MacGregor; Mark J Smyth
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

View more
  95 in total

Review 1.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

Review 2.  A systematic review of the association between immunogenomic markers and cancer-related fatigue.

Authors:  L N Saligan; H S Kim
Journal:  Brain Behav Immun       Date:  2012-05-14       Impact factor: 7.217

Review 3.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

4.  Development of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1.

Authors:  Mina Ebrahimi; Tohid Kazemi; Mazdak Ganjalikhani-Hakemi; Jafar Majidi; Hossein Khanahmad; Ilnaz Rahimmanesh; Vida Homayouni; Shirin Kohpayeh
Journal:  Iran J Biotechnol       Date:  2015-12       Impact factor: 1.671

Review 5.  The reactive stroma microenvironment and prostate cancer progression.

Authors:  David A Barron; David R Rowley
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

Review 6.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

7.  T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.

Authors:  Matthew D Morse; Douglas G McNeel
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

8.  Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy.

Authors:  M Giuliani; L R Sampson; O Wong; J Gay; L W Le; B C J Cho; A Brade; A Sun; A Bezjak; A J Hope
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

Review 9.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147

Review 10.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.